Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Recurrent Platinum Resistant Ovarian Cancer
Interventions: cediranib and olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 25
States / cities: Mobile, Alabama • Anchorage, Alaska • Downey, California + 21 more

Conditions: Type 1 Diabetes, Eating Disorder
Interventions: Not listed
Lead sponsor: HealthPartners Institute; Other
Eligibility: 12 Years and older
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Anorexia, Cachexia, Weight Loss
Interventions: Megestrol acetate concentrated suspension 110 mg/mL, Placebo; Drug
Lead sponsor: Par Pharmaceutical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 3
States / cities: Miami, Florida • Cumberland, Maryland • Mt. Pleasant, South Carolina

Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions: NNC0487-0111, Semaglutide, Placebo (matched to NNC0487-0111), Placebo (matched to semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 985 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Hollywood, Florida • Orange City, Florida • Weston, Florida + 7 more

Conditions: Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer, Extragonadal Germ Cell Tumor, Gastric Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions: lapatinib, paclitaxel; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetic Foot Ulcer
Interventions: Celliant Diabetic Medical Socks, Control (placebo) Medical Socks; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 22 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions: BI 10773, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 18
States / cities: Anaheim, California • Lomita, California • Plantation, Florida + 15 more

Conditions: Adenocarcinoma of the Ovary
Interventions: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine; Biological
Lead sponsor: AVAX Technologies; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 3
States / cities: Zion, Illinois • Tulsa, Oklahoma • Philadelphia, Pennsylvania

Conditions: Type 1 Diabetes Mellitus
Interventions: Technosphere Insulin Inhalation Powder, Rapid Acting Analog; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Paclitaxel, Carboplatin, Bevacizumab, IMNN-001; Drug
Lead sponsor: Imunon; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Baltimore, Maryland • New York, New York • Oklahoma City, Oklahoma + 1 more

Conditions: Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Interventions: Cositecan, Pharmacological Study; Drug · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Type 2 Diabetes Mellitus
Interventions: Paleolithic diet, ADA ( American Diabetes Association) recommended diet; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pancreatic Neoplasm
Interventions: 22G ProCore biopsy needle, 22G standard FNA needle; Procedure
Lead sponsor: AdventHealth; Other
Eligibility: 19 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis
Interventions: Paricalcitol, Cinacalcet; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 30
States / cities: Tempe, Arizona • Chula Vista, California • Los Angeles, California + 22 more

Conditions: Thyroid Cancer, Graves Disease
Interventions: Cervical Collar Therapy Indicator (COTI); Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK1614235, Sitagliptin, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Miami, Florida • Baton Rouge, Louisiana • Cincinnati, Ohio

Conditions: Pancreatic Cancer
Interventions: capecitabine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypertension, Diabete Type 2
Interventions: Treatment as Usual Plus Occupational Therapy, Treatment as Usual; Behavioral
Lead sponsor: University of Indianapolis; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Obesity, Diabetes Mellitus, Type 2, Appetitive Behavior
Interventions: Cracked whole wheat porridge, Semolina wheat porridge, Whole wheat flour porridge, Refined wheat flour porridge, Refined wheat flour porridge,fine bran, Refined wheat flour porridge,coarse bran; Other
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Diabetic Retinopathy, Low Vision
Interventions: Eye4, Placebo; Device · Other
Lead sponsor: Eyedaptic; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: Physical Activity, Breast Cancer, Cervical Cancer, Ovarian Cancer, Endometrial Cancer
Interventions: Hula; Behavioral
Lead sponsor: University of Hawaii; Other
Eligibility: 21 Years and older · Female only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Colorectal Cancer, Pancreatic Cancer, Lung Cancer
Interventions: Vitamin C; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Diabetes Mellitus, Type 1 Diabetes
Interventions: Culturally and linguistically tailored onboarding and support program, Medtronic MiniMed 780G Insulin Pump System; Other · Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years to 20 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
Interventions: BYL719, AMG 479; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more

Search by objective public record fields.

Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes.

Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

Celliant Socks to Increase Tissue Oxygenation and Complete Wound Closure in Diabetic Foot Wounds

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer

Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Paleolithic Diets vs T2D and Improvements in the Metabolic Syndrome

22G FNA Needle vs. 22G ProCore Needle

Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D

Personalized Treatment in Thyroid Disorders

A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes

Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene

Effect of Occupational Therapy in Promoting Medication Adherence

Whole Grains, Gastric Emptying and Glycemic Response

Diabetic Retinopathy Tethered Augmented Reality With Eye4 Study

Hula, a Physical Activity Intervention for Female-Cancer Survivors

High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies

Supporting Medtronic 780G Insulin Pump Adoption in Latino Patients: A Spanish - Language Training Initiative

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors